Harry J. Leonhardt
2006 - Senomyx
In 2006, Harry J. Leonhardt earned a total compensation of $755.9K as Senior Vice President, General Counsel and Corporate Secretary at Senomyx.
Compensation breakdown
| Non-Equity Incentive Plan | $69,960 |
|---|---|
| Option Awards | $411,361 |
| Salary | $274,588 |
| Total | $755,909 |
Leonhardt received $411.4K in option awards, accounting for 54% of the total pay in 2006.
Leonhardt also received $70K in non-equity incentive plan and $274.6K in salary.
Rankings
In 2006, Harry J. Leonhardt's compensation ranked 3,718th out of 7,022 executives tracked by ExecPay. In other words, Leonhardt earned more than 47.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,718 out of 7,022 | 47th |
Division Services | 472 out of 916 | 49th |
Major group Engineering, Accounting, Research, Management, And Related Services | 46 out of 97 | 53rd |
Industry group Research, Development, And Testing Services | 19 out of 43 | 56th |
Industry Commercial Physical and Biological Research | 19 out of 43 | 56th |
Source: SEC filing on April 25, 2008.
Leonhardt's colleagues
We found four more compensation records of executives who worked with Harry J. Leonhardt at Senomyx in 2006.
2006
Kent Snyder
Senomyx
Chief Executive Officer
2006
John Poyhonen
Senomyx
Senior Vice President and Chief Financial and Business Officer
2006
Mark Zoller
Senomyx
Chief Scientific Officer
2006
Sharon Wicker
Senomyx
Senior Vice President of Commercial Development and Chief Strategy Officer
News
Poseida Therapeutics CEO Mark Gergen's 2022 pay jumps 55% to $4.4M
April 26, 2023
Poseida Therapeutics CEO Eric Ostertag's 2021 pay jumps 633% to $6.3M
April 27, 2022
Halozyme Therapeutics CEO Helen Torley's 2019 pay rises 1% to $5.9M
March 20, 2020
Halozyme Therapeutics CEO Helen Torley's 2018 pay rises 12% to $5.8M
March 22, 2019